Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Nicole, Grunenberg"'
Autor:
Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, One B Dintwe, Faatima Laher Omar, Jia J Kee, Linda-Gail Bekker, Fatima Laher, Nivashnee Naicker, Ilesh Jani, Nyaradzo M Mgodi, Portia Hunidzarira, Modulakgota Sebe, Maurine D Miner, Laura Polakowski, Shelly Ramirez, Michelle Nebergall, Simbarashe Takuva, Lerato Sikhosana, Jack Heptinstall, Kelly E Seaton, Stephen De Rosa, Carlos A Diazgranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Susan W Barnett, Niranjan Kanesa-Thasan, James G Kublin, Georgia D Tomaras, M Juliana McElrath, Lawrence Corey, Kathryn Mngadi, Paul Goepfert, HVTN 107 Protocol Team
Publikováno v:
PLoS Medicine, Vol 21, Iss 3, p e1004360 (2024)
BackgroundAdjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the RV144-like HIV vaccine regimen
Externí odkaz:
https://doaj.org/article/909a7c021d8247d2955cca75b0f8a084
Autor:
Ying Huang, Shomoita Alam, Erica Andersen-Nissen, Lindsay N. Carpp, One B. Dintwe, Britta S. Flach, Nicole Grunenberg, Fatima Laher, Stephen C. De Rosa, Guido Ferrari, Craig Innes, Linda-Gail Bekker, James G. Kublin, M. Juliana McElrath, Georgia D. Tomaras, Glenda E. Gray, Peter B. Gilbert
Publikováno v:
Viruses, Vol 16, Iss 9, p 1365 (2024)
Identifying correlations between immune responses elicited via HIV and non-HIV vaccines could aid the search for correlates of HIV protection and increase statistical power in HIV vaccine-efficacy trial designs. An exploratory objective of the HVTN 0
Externí odkaz:
https://doaj.org/article/342eca49e116452ab91a719fe4d9dcad
Autor:
Maurine D. Miner, Allan deCamp, Nicole Grunenberg, Stephen C. De Rosa, Andrew Fiore-Gartland, Katherine Bar, Paul Spearman, Mary Allen, Pei-Chun Yu, Bryce Manso, Nicole Frahm, Spyros Kalams, Lindsey Baden, Michael C. Keefer, Hyman M. Scott, Richard Novak, Hong Van Tieu, Georgia D. Tomaras, James G. Kublin, M. Juliana McElrath, Lawrence Corey, Ian Frank, Artur Kalichman, Paul Edlefsen, Mary Enama, John Hural, Renee Holt, Debora Dunbar, Dave Crawford, Ian Maki, Jan Johannessen, Scharla Estep, Yevgeny Grigoriev, Tamra Madenwald, Marianne Hansen, Drienna Holman, Ramey Fair, Genevieve Meyer, Anya Luke-Kilolam
Publikováno v:
EBioMedicine, Vol 100, Iss , Pp 104987- (2024)
Summary: Background: Elicitation of broad immune responses is understood to be required for an efficacious preventative HIV vaccine. This Phase 1 randomized controlled trial evaluated whether administration of vaccine antigens separated at multiple i
Externí odkaz:
https://doaj.org/article/3601d1aade9f4c80b11f6ab0b201ca6f
Autor:
Rujeko Mashingaidze, Zoe Moodie, Mary Allen, Linda-Gail Bekker, Doug Grove, Nicole Grunenberg, Yunda Huang, Holly E Janes, Erica Maxine Lazarus, Mookho Malahleha, Maphoshane Nchabeleng, Fatima Laher
Publikováno v:
PLOS Global Public Health, Vol 3, Iss 4, p e0001782 (2023)
There is limited data about bacterial STIs in MSM populations in sub-Saharan Africa. Our retrospective analysis used data from the HVTN 702 HIV vaccine clinical trial (October 2016 to July 2021). We evaluated multiple variables. Polymerase chain reac
Externí odkaz:
https://doaj.org/article/8c2323d8afd840b6b67a1f0bd8ab42d7
Autor:
Kelly E. Seaton, Aaron Deal, Xue Han, Shuying S. Li, Ashley Clayton, Jack Heptinstall, Ann Duerr, Mary A. Allen, Xiaoying Shen, Sheetal Sawant, Nicole L. Yates, Paul Spearman, Gavin Churchyard, Paul A. Goepfert, Janine Maenza, Glenda Gray, Giuseppe Pantaleo, Laura Polakowski, Harriet L. Robinson, Shannon Grant, April K. Randhawa, Ying Huang, Cecilia Morgan, Nicole Grunenberg, Shelly Karuna, Peter B. Gilbert, M. Juliana McElrath, Yunda Huang, Georgia D. Tomaras, NIAID HIV Vaccine Trials Network (HVTN) 076, 088, 086, 096, 097, 205 Study Teams
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
Abstract We studied mucosal immune responses in six HIV-1 vaccine trials investigating different envelope (Env)-containing immunogens. Regimens were classified into four categories: DNA/vector, DNA/vector plus protein, protein alone, and vector alone
Externí odkaz:
https://doaj.org/article/2f212191b8044471a09de9b169fd03d0
Autor:
Erica Andersen-Nissen, Andrew Fiore-Gartland, Lamar Ballweber Fleming, Lindsay N Carpp, Anneta F Naidoo, Michael S Harper, Valentin Voillet, Nicole Grunenberg, Fatima Laher, Craig Innes, Linda-Gail Bekker, James G Kublin, Ying Huang, Guido Ferrari, Georgia D Tomaras, Glenda Gray, Peter B Gilbert, M Juliana McElrath
Publikováno v:
PLoS Pathogens, Vol 17, Iss 3, p e1009363 (2021)
The pox-protein regimen tested in the RV144 trial is the only vaccine strategy demonstrated to prevent HIV-1 infection. Subsequent analyses identified antibody and cellular immune responses as correlates of risk (CoRs) for HIV infection. Early predic
Externí odkaz:
https://doaj.org/article/5a0b9dc7456e43099784dfcec3d30a7c
Autor:
Zoe Moodie, Stephen R Walsh, Fatima Laher, Lucas Maganga, Michael E Herce, Sarita Naidoo, Mina C Hosseinipour, Craig Innes, Linda-Gail Bekker, Nicole Grunenberg, Philipp Mann, Chenchen Yu, Allan C deCamp, Maurine D Miner, Nicole L Yates, Jack Heptinstall, Nonhlanhla N Mkhize, One Dintwe, Nicole Frahm, Kristen W Cohen, Mary Allen, Julia Hutter, Ralf Wagner, Giuseppe Pantaleo, M Juliana McElrath, Georgia D Tomaras, Lynn Morris, David C Montefiori, Erica Andersen-Nissen, Glenda E Gray, Peter B Gilbert, James G Kublin, NIAID HVTN 100 and HVTN 111 trial teams
Publikováno v:
PLoS Medicine, Vol 17, Iss 5, p e1003117 (2020)
BackgroundDNA plasmids promise a pragmatic alternative to viral vectors for prime-boost HIV-1 vaccines. We evaluated DNA plasmid versus canarypox virus (ALVAC) primes in 2 randomized, double-blind, placebo-controlled trials in southern Africa with ha
Externí odkaz:
https://doaj.org/article/7c285a3459774f30806f3e5507798d93
Autor:
Fatima Laher, Zoe Moodie, Kristen W Cohen, Nicole Grunenberg, Linda-Gail Bekker, Mary Allen, Nicole Frahm, Nicole L Yates, Lynn Morris, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Kevin Saunders, Shannon Grant, Chenchen Yu, Peter B Gilbert, Sanjay Phogat, Carlos A DiazGranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Carter Bentley, Nonhlanhla N Mkhize, Michael N Pensiero, Vijay L Mehra, James G Kublin, Lawrence Corey, David C Montefiori, Glenda E Gray, M Juliana McElrath, Georgia D Tomaras
Publikováno v:
PLoS Medicine, Vol 17, Iss 2, p e1003038 (2020)
BackgroundHVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses.Methods and findingsA phase 1-2 randomized double-blind placebo-co
Externí odkaz:
https://doaj.org/article/a8f5e1efa20e4dca897e71b9fcfdaef2
Autor:
Gustavo H, Dayan, Nadine, Rouphael, Stephen R, Walsh, Aiying, Chen, Nicole, Grunenberg, Mary, Allen, Johannes, Antony, Kwaku Poku, Asante, Amit Suresh, Bhate, Tatiana, Beresnev, Matthew I, Bonaparte, Maria, Angeles Ceregido, Dmytro, Dobrianskyi, Bo, Fu, Marie-Helene, Grillet, Maryam, Keshtkar-Jahromi, Michal, Juraska, Jia Jin, Kee, Hannah, Kibuuka, Marguerite, Koutsoukos, Roger, Masotti, Nelson L, Michael, Humberto, Reynales, Merlin L, Robb, Sandra M, Villagómez Martínez, Fredrick, Sawe, Lode, Schuerman, Tina, Tong, John, Treanor, T Anh, Wartel, Carlos A, Diazgranados, Roman M, Chicz, Sanjay, Gurunathan, Stephen, Savarino, Saranya, Sridhar
Publikováno v:
medRxiv : the preprint server for health sciences.
BackgroundCOVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern.MethodsWe conducted a global Phase 3, multi-stage efficacy study (NCT04904549) among adults
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a3f37b0909ef7e92d9ce42be164f664
https://pubmed.ncbi.nlm.nih.gov/36523415
https://pubmed.ncbi.nlm.nih.gov/36523415
Autor:
Kenneth H Mayer, Kelly E Seaton, Yunda Huang, Nicole Grunenberg, Abby Isaacs, Mary Allen, Julie E Ledgerwood, Ian Frank, Magdalena E Sobieszczyk, Lindsey R Baden, Benigno Rodriguez, Hong Van Tieu, Georgia D Tomaras, Aaron Deal, Derrick Goodman, Robert T Bailer, Guido Ferrari, Ryan Jensen, John Hural, Barney S Graham, John R Mascola, Lawrence Corey, David C Montefiori, HVTN 104 Protocol Team, and the NIAID HIV Vaccine Trials Network
Publikováno v:
PLoS Medicine, Vol 14, Iss 11, p e1002435 (2017)
BACKGROUND:VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active against a broad range of HIV-1 primary isolates in vitro and protects against simian-human immunodeficiency virus (SHIV) when delivered parenterally to
Externí odkaz:
https://doaj.org/article/b3def334b9d34d36925838d06d4bd961